secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ensysce Biosciences, Inc. (ENSC)
CIK:        0001716947
Form:       8-K
Filed at:   2025-03-10T23:59:59+00:00
Accession:  0001493152-25-009695
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ensysce reports Q4 net loss $3.6M, cash $3.5M; signs PF614 commercial launch partner
--------------------------------------------------------------------------------

- Cash $3.5M at Dec 2024 vs $4.2M Sept 2024 and $1.1M Dec 2023; 2024 net loss $8.0M vs $10.6M in 2023.
- Entered strategic partnership with specialty manufacturer for commercial launch of PF614 and PF614-MPAR.
- PF614-MPAR-102 interim data show overdose protection at 100 mg dose; study continues at higher doses.
- FDA feedback on PF614 phase 3 design received; enrollment expected Q2 2025; NDA submission targeted for 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716947/000149315225009695/0001493152-25-009695-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716947/000149315225009695/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-009695

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer